The Lancet: The results of phase II clinical trials of the COVID-19 vaccine at Oxford University were positive

20, 2020 // -- The CHAdOx1 nCoV-19 vaccine for SARS-CoV-2 in the United Kingdom showed the same safety and immunogenicity in healthy older adults (56 years and older) as adults aged 18-55 years, according to the latest results published in The Lancet.
phase II trial found that the vaccine did not cause side effects at all ages and at low and standard doses.
causes a T-cell response within 14 days of the first dose of the vaccine (i.e., a cellular immune response, which can detect and attack infected cells) and an antibody response within 28 days of enhanced vaccination (i.e., a body fluid immune response, which can detect and attack the virus as it spreads).
is currently conducting Phase 3 trials to confirm these results, as well as the effectiveness of the vaccine in preventing SARS-CoV-2 infection, for a wider population, including older persons with basic health conditions.
Lead author of the study, Professor Andrew Pollard, of the University of Oxford, UK, said.com: "Because the immune system of older people deteriorates with age, the vaccine's immune response tends to decrease, which also makes older people more susceptible to infection.
study, co-author Dr Mahshi Ramasamy, of the University of Oxford, added: "In our study, older people developed strong antibodies and T-cell reactions after vaccination.
hope that our vaccine will help protect some of the most vulnerable in society, but further research is needed before we can be sure."
" This new study is the fifth public clinical trial of the SARS-CoV-2 vaccine tested in the adult adults.
also shown that other COVID-19 vaccines can produce immune responses in older adults, but it is difficult to compare results between studies.
in a phase 2 trial released today, 560 participants (160 aged 18-55, 160 aged 56-69 and 240 aged 70 or over) were divided into 10 groups, receiving low doses of the ChaAdOx1 nCoV-19 vaccine or a controlled vaccine (meningococcal-binding vaccine).
over the age of 55 were also divided into groups, receiving a single dose of the vaccine or two vaccinations 28 days apart.
before being vaccinated, all participants were given blood tests to determine if they had previously been infected with SARS-CoV-2, and people with SARS-CoV-2 antibodies were excluded.
participants aged 18-55 who received two standard doses of the Oxford COVID-19 vaccine, as well as all participants aged 56 or over, were assessed for an immune response 1, 2 and 4 weeks after the first and second doses on the day of vaccination.
results showed mild adverse reactions to the ChAdOx1 nCoV-19 vaccine (the most common effects were pain and pain at the injection site, fatigue, headache, fever, and muscle pain), but were more common than the controlled vaccine.
the six months since the dose was given, there have been 13 serious adverse events that have nothing to do with vaccination.
() Source: Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and challenges immune response Original source: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine a prime-regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial, The Lancet (2020). DOI: 10.1016/S0140-6736 (20) 32466-1 , ... (20) 32466-1 / fulltext